Blueprint Medicines (BPMC) announced that it had achieved positive results from a phase 2 study using its cancer drug avapritinib treating patients with indolent systemic mastocytosis (SM). Not only did this drug achieve the clinical endpoints, but it is able to move on to part 2 of the study. That's because now it has the best recommended dose to move forward with and prove that the drug works for this rare disease population. Avapritinib is also going to be advanced for advanced systemic mastocytosis (ASM). This will provide another opportunity in the same